BioSpace News Archive

Schrödinger, Inc. reported that on February 13, 2024, the company granted non-statutory stock options to purchase 4,800 shares of the company’s common stock to four newly hired employees and restricted stock units with respect to 5,550 shares of the company’s common stock to eight newly hired employees.

Otsuka Pharmaceutical Development & Commercialization, Inc., ; Otsuka Pharmaceutical, Co. Ltd. ; and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy.

MDxHealth SA, a commercial-stage precision diagnostics company, announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth.

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter and year ended December 31, 2023 after the market closes on Tuesday, February 27, 2024.

Bayer AG and Asklepios BioPharmaceutical, Inc. announced that the first patient has been randomized in GenePHIT, a Phase II trial of AB-1002 for the treatment of congestive heart failure.

The board of directors of Abbott declared a quarterly common dividend of 55 cents per share.

The U.S. Food and Drug Administration approved Xolair injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions, including reducing the risk of anaphylaxis, that may occur with accidental exposure to one or more foods.

This announcement is a summary of Bioretec Ltd’s financial statements bulletin for January-December 2023.

Biodesix, Inc., a leading diagnostic solutions company with a focus in lung disease, announced that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting taking place in Washington, DC from February 23-26.